Dysfunctional High-density lipoprotein and the potential of Apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins

Circulation Journal

Volumn 75, Issue 7, 2011, Pages 1533-1538

  Imaizumi, Satoshi ^a   Navab, Mohamad ^a   Morgantini, Cecilia ^c   Charles Schoeman, Christina ^a   Su, Feng ^a   Gao, Feng ^a   Kwon, Murray ^a   Ganapathy, Ekambaram ^a   Meriwether, David ^a   Farias Eisner, Robin ^a   Fogelman, Alan M ^a   Reddy, Srinivasa T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

ApoA I mimetic peptides; High density lipoprotein; Inflammation; Oxidative stress

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MIMETIC PEPTIDE 4F; APOLIPOPROTEIN A1 MIMETIC PEPTIDE 5F; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; PREALBUMIN; TRANSFERRIN; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; CANCER INHIBITION; CHOLESTEROL TRANSPORT; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN FUNCTION; LIPOPROTEIN SYNTHESIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PROGNOSIS; PROTEIN CONTENT; PROTEIN FUNCTION; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; APOLIPOPROTEIN A-I; BIOMIMETICS; CORONARY DISEASE; DISEASE MODELS, ANIMAL; HUMANS; LIPOPROTEINS, HDL; MICE; PEPTIDES;

EID: 79959758715     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0460     Document Type: Review

References (55)

1. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85: 1234-1241.
2. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-1 gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91: 9607-9611.
3. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292-2300.
4. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007; 297: 1675-1682.
5. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, et al. Studies of synthetic peptide analogs of the amphipathic helix: Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 1985; 260: 10248-10255.
6. Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, et al. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class a amphipathic peptides. Biochemistry 1995; 34: 7955-7965.
7. Venkatachalapathi YV, Phillips MC, Epand RM, Epand RF, Tytler EM, Segrest JP, et al. Effect of end group blockage on the properties of a class a amphipathic helical peptide. Proteins 1993; 15: 349-359.
8. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, et al. Effects of increasing hydrophobicity on the physicalchemical and biological properties of a class a amphipathic helical peptide. J Lipid Res 2001; 42: 1096-1104.
9. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
10. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res 2000; 41: 1481-1494.
11. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, et al. A new synthetic class a amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42: 545-552.
12. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290-292.
13. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, et al. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 2005; 111: 3126-3134.
14. Peterson SJ, Husney D, Kruger AL, Olszanecki R, Ricci F, Rodella LF, et al. Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther 2007; 322: 514-520.
15. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, et al. L-4f treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 2008; 49: 1658-1669.
16. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 2009; 50: 1293-1304.
17. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002; 106: 1127-1132.
18. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 2007; 293: H1432-H1441.
19. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107: 2337-2341.
20. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on western diet. Circ Res 2005; 97: 1190-1197.
21. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol 2008; 173: 993-1001.
22. Handattu SP, Garber DW, Monroe CE, van Groen T, Kadish I, Nayyar G, et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of alzheimer's disease. Neurobiol Dis 2009; 34: 525-534.
23. Buga GM, Frank JS, Mottino GA, Hendizadeh M, Hakhamian A, Tillisch JH, et al. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a western diet. J Lipid Res 2006; 47: 2148-2160.
24. Buga GM, Frank JS, Mottino GA, Hakhamian A, Narasimha A, Watson AD, et al. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a western diet. J Lipid Res 2008; 49: 192-205.
25. Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, et al. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol 2010; 30: 283-289.
26. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1426-1432.
27. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, et al. Differential effects of apolipoprotein A-1-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110: 1701-1705.
28. Hsieh GR, Schnickel GT, Garcia C, Shefizadeh A, Fishbein MC, Ardehali A. Inflammation/oxidation in chronic rejection: Apolipoprotein A-1 mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007; 84: 238-243.
29. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-1 mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49: 1344-1352.
30. Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010; 12: R93.
31. Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008; 127: 234-244.
32. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice: A novel biomarker of atherosclerosis. J Biol Chem 2007; 282: 23698-23707.
33. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-1. J Lipid Res 2008; 49: 2302-2311.
34. Dai L, Datta G, Zhang Z, Gupta H, Patel R, Honavar J, et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 2010; 51: 2695-2705.
35. Smythies LE, White CR, Maheshwari A, Palgunachari MN, Anantharamaiah GM, Chaddha M, et al. Apolipoprotein A-1 mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 2010; 298: C1538-1548.
36. Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, et al. Altered activities of anti-atherogenic enzymes lcat, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis- susceptible mice. J Lipid Res 2002; 43: 477-485.
37. Mukamal KJ, Pai JK, Jensen MK, Rimm EB. Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men. Circ J 2009; 73: 1302-1307.
38. Mashiba J, Koike G, Kamiunten H, Ikeda M, Sunagawa K. Vasospastic angina and microvascular angina are differentially influenced by PON1 A632G polymorphism in the Japanese. Circ J 2005; 69: 1466-1471.
39. Vakili L, Hama S, Kim JB, Tien D, Safarpoor S, Ly N, et al. The effect of HDL mimetic peptide 4F on PON1. Adv Exp Med Biol 2010; 660: 167-172.
40. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamiah GM, et al. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 2010; 4: 139-148.
41. Fluiter K, Sattler W, De Beer MC, Connell PM, van der Westhuyzen DR, van Berkel TJ. Scavenger receptor B1 mediates the selective uptake of oxidized cholesterol esters by rat liver. J Biol Chem 1999; 274: 8893-8899.
42. Fluiter K, van der Westhuijzen DR, van Berkel TJ. In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and kupffer cells. J Biol Chem 1998; 273: 8434-8438.
43. Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman AM, Reddy ST. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 2010; 59: 3223-3228.
44. Morgantini C, Natali A, Boldrini B, Navab M, Fogelman AM, Ferrannini E, et al. Anti-inflammatory and anti-oxidant properties of high density lipoproteins (HDL) are impaired in type 2 diabetes. In: Proceedings of American Diabetes Association's 71st Scientific Sessions, June 2011 [Supplement to Diabetes].
45. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange proteinchips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-12348.
46. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Erel O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 2009; 112: 481-485.
47. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 2010; 107: 19997-20002.
48. Samadi N, Bekele R, Capatos D, Venkatraman G, Sariahmetoglu M, Brindley DN. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 2011; 93: 61-70.
49. Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) 2011; 3: 479-489.
50. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the anti-oxidant enzyme MnSOD. Int J Cancer 2011 [Epub ahead of print].
51. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hama S, Reddy ST, et al. Lipoprotein inflammatory properties and serum amyloid a levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007; 48: 2344-2353.
52. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, et al. Treatment of patients with cardiovascular disease with L-4F, an apoA-I mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011; 52: 361-373.
53. Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hough G, Hama S, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether the peptide is administered subcutaneously or orally. J Lipid Res 2011; 52: 1200-1210.
54. Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-2270.
55. Miyauchi K, Daida H. Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease: LDL-cholesterol: The lower, the better; is it true for Asians? (Pro) Circ J 2010; 74: 1718-1730.